Noticias de PFE_US
Noticias del mercado
Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Pfizer Inc. stock has climbed toward a new 52-week high around late August and early September 2026,
Pfizer and BioNTech previously received FDA approval for their 2026–2027 COMIRNATY XFG mRNA COVID-19 vaccine, tailored to the XFG variant, for adults 65+ and high-risk individuals aged 5–64, with U.S. distribution beginning shortly after approval. This targeted approval keeps Pfizer’s mRNA platform actively in use for high‑risk populations and aligns the company’s vaccine portfolio with the FDA’s latest variant-composition guidance. We’ll now examine how ongoing XFG-variant vaccine shipments...
Pfizer stock trades in the high-$27 range as of August 31, 2026, while a newly approved XFG-adapted
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
Página 31 de 34